Cargando…

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)

Humira® (adalimumab) is a recombinant human IgG1 monoclonal antibody (mAb) glycoprotein consisting of 1330 amino acids that is specific for human tumor necrosis factor (TNF). The biological activity and clinical profile of mAb therapeutics, including adalimumab, is influenced by their protein struct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tebbey, Paul W, Varga, Amy, Naill, Michael, Clewell, Jerry, Venema, Jaap
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622832/ https://www.ncbi.nlm.nih.gov/pubmed/26230301 http://dx.doi.org/10.1080/19420862.2015.1073429

Ejemplares similares

Adalimumab (Humira™) in Ophthalmology: A Review of the Literature
por: Neri, Piergiorgio, et al.
Publicado: (2010)

Adalimumab (Humira) induced acute lung injury
por: Kohli, Ritesh, et al.
Publicado: (2013)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
por: Zhang, Erhui, et al.
Publicado: (2020)

Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
por: Magnenat, Laurent, et al.
Publicado: (2016)

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
por: Kwon, Joon-Cheol, et al.
Publicado: (2021)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects
por: Hyland, Elizabeth, et al.
Publicado: (2016)

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects
por: Hillson, Jan, et al.
Publicado: (2018)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
por: Van den Bosch, Filip, et al.
Publicado: (2017)

Erratum to: Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study
por: Van den Bosch, Filip, et al.
Publicado: (2017)

Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
por: Vural, Sevilay, et al.
Publicado: (2022)

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy
por: Sinha, Shubhadeep, et al.
Publicado: (2020)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis
por: Jani, Rajendrakumar H., et al.
Publicado: (2015)

Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations
por: Kaneko, Kayoko, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
por: Su, Jinmei, et al.
Publicado: (2020)

Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components
por: Torkashvand, Fatemeh, et al.
Publicado: (2017)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Multi-attribute Raman spectroscopy (MARS) for monitoring product quality attributes in formulated monoclonal antibody therapeutics
por: Wei, Bingchuan, et al.
Publicado: (2021)

Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab
por: Lee, Nayoung, et al.
Publicado: (2018)

Exploring the analytical power of the QTOF MS platform to assess monoclonal antibodies quality attributes
por: Gomes, Ricardo A., et al.
Publicado: (2019)

Design and Evaluation of a Multiplexed Assay to Assess Human Immunogenicity Against Humira®
por: Alleyn, Matthew, et al.
Publicado: (2020)

Improved production of Humira antibody in the genetically engineered Escherichia coli SHuffle, by co-expression of human PDI-GPx7 fusions
por: Lénon, Marine, et al.
Publicado: (2020)

The impact of microcarrier culture optimization on the glycosylation profile of a monoclonal antibody
por: Costa, Ana Rita, et al.
Publicado: (2013)

A Cancer-specific Monoclonal Antibody Recognizes the Aberrantly Glycosylated Podoplanin
por: Kato, Yukinari, et al.
Publicado: (2014)

In-Depth Method for the Characterization of Glycosylation in Manufactured Recombinant Monoclonal Antibody Drugs
por: Song, Ting, et al.
Publicado: (2014)

Antibody glycosylation correlates with disease progression in SIV‐ Mycobacterium tuberculosis coinfected cynomolgus macaques
por: Haycroft, Ebene R, et al.
Publicado: (2023)

Clinical Evaluation of Humira(®) Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics
por: Dillingh, Marlous R., et al.
Publicado: (2016)

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
por: Cohen, Stanley B, et al.
Publicado: (2018)

Similar Pharmacokinetics of the Adalimumab (Humira(®)) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE(®)-AI and VOLTAIRE(®)-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials
por: Ramael, Steven, et al.
Publicado: (2018)

Ulcerative Tuberculosis in a Patient Treated with Adalimumab
por: VARPULUOMA, Outi, et al.
Publicado: (2022)

Establishment of a highly precise multi-attribute method for the characterization and quality control of therapeutic monoclonal antibodies
por: Tajiri-Tsukada, Michiko, et al.
Publicado: (2020)

A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program
por: Karlsdottir, Kristin, et al.
Publicado: (2022)

Determination of Peptide Profile Consistency and Safety of Collagen Hydrolysates as Quality Attributes
por: López‐Morales, Carlos A., et al.
Publicado: (2019)

Application of NMR and Chemometric Analyses to Better Understand the Quality Attributes in pH and Thermally Degraded Monoclonal Antibodies
por: Beaumont, Victor A., et al.
Publicado: (2023)

Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation
por: Perez, Norma, et al.
Publicado: (2004)

Characterisation of monoclonal antibodies specific for hamster leukocyte differentiation molecules
por: Rees, Jennifer, et al.
Publicado: (2017)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
por: Alsamil, Ali M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ua4r9tqjt0hsp4ginogh3833qb